Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine extended-release) as an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The Trevi Therapeutics news feed on this page brings together company announcements, clinical data updates, and financial disclosures that relate directly to TRVI stock and its development programs.
News items commonly include results from key clinical trials such as the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, along with information on additional studies like respiratory safety and drug–drug interaction trials. Trevi’s releases also describe regulatory milestones, including End-of-Phase 2 interactions with the U.S. Food and Drug Administration for chronic cough in IPF, and outline planned Phase 3 and Phase 2b programs.
Investors and followers of TRVI can also find corporate and financial updates in the news stream, including quarterly financial results, capital-raising transactions, and participation in healthcare and investor conferences. Management changes and other material events are typically reported through press releases that are also furnished to the U.S. Securities and Exchange Commission on Form 8-K.
By reviewing the Trevi Therapeutics news page, readers can monitor how the company reports progress in its chronic cough indications, how clinical data are presented at scientific meetings, and how management describes its strategy for advancing Haduvio. This centralized news view helps provide context for developments that may influence perceptions of Trevi’s clinical pipeline and regulatory trajectory.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) reported Q1 2024 financial results and business updates, reaffirming guidance for Phase 2a RIVER trial and HAP Study. Topline data for both trials expected in 2024. IND cleared for Phase 1b trial. Key business updates include progress in clinical trials, with Phase 2a RIVER trial and Phase 2b CORAL trial enrollment ongoing. The company ended Q1 2024 with $72.8 million in cash. Financially, R&D expenses increased to $8.8 million, G&A expenses were $3.1 million, with a net loss of $10.9 million. Conference call/webcast and upcoming meetings announced for investor participation.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will host a conference call and webcast on May 7, 2024, to discuss the corporate update and financial results for the first quarter of 2024. The company is developing Haduvio™ for chronic cough in IPF and RCC. Investors can participate via phone or webcast.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.